Search

We have set out to develop a drone, based on the existing Delftacopter, capable of soil monitoring via LiDAR remote sensing. The battery was to be replaced by a fuel cell system in order to extend the range threefold to 180km. Unfortunately, the ultimate design is likely unfeasible. Agriculture requires healthy soil and monitoring soil health is fundamental to its maintenance. Soil organic carbon in particular provides energy to the soil’s microorganisms, and is beneficial to water and nutrient retention. In addition, storing carbon in the soil is a form of carbon sequestration, which has become interesting due to the rising levels of carbon dioxide in our atmosphere. Monitoring soil organic carbon is therefore the goal of the drone design. The fuel cell system is a 650Whydrogen fuel cell by Intelligent Energy with a mass of 1290 g, which will be replacing the battery in the base design. Fuel tanks that were considered suitable are the 450 g, 0.5 L, 500 bar and 1350 g, 3 L, 300 bar fuel tanks by Meyer. It was found that one 1350 g and two 450 g fuel tanks were necessary to achieve the desired range of 180 km. However, after more careful drag estimates, this configuration turns out to be too heavy. 4 450 g fuel tanks remains feasible. Results below are based on this amount of fuel tanks. The incorporated LiDAR sensor is one by Velodyne, namely the Puck LITE, with a specified range of 100 m. The LiDAR sensor has a firing cycle of 55.296 &s, almost 20 kHz. Based on previous studies that used LiDAR to measure soil organic carbon, it has been established that a density of 5 data points per square meter is required. Fromour LiDAR parameters it turns out that the optimal flight altitude is 27.5mabove the surface that is to be measured, with a rotation rate of 10 Hz for the LiDAR sensor, when flying at a speed of 20ms¡1. With a flight distance of roughly 116km at 22.5ms¡1 (111km at 20ms¡1), an area of 21.8km2 per flight can be scanned. 1

Excessive inflammation and failed resolution of the inflammatory response are underlying components of numerous conditions such as arthritis, cardiovascular disease, and cancer. Hence, therapeutics that dampen inflammation and enhance resolution are of considerable interest. In this study, we demonstrate the proresolving activity of sub–100-nm nanoparticles (NPs) containing the anti-inflammatory peptide Ac2-26, an annexin A1/lipocortin 1-mimetic peptide. These NPs were engineered using biodegradable diblock poly(lactic-co-glycolic acid)-b-polyethyleneglycol and poly(lactic-co-glycolic acid)-b-polyethyleneglycol collagen IV–targeted polymers. Using a self-limited zymosan-induced peritonitis model, we show that the Ac2-26 NPs (100 ng per mouse) were significantly more potent than Ac2-26 native peptide at limiting recruitment of polymononuclear neutrophils (56% vs. 30%) and at decreasing the resolution interval up to 4 h. Moreover, systemic administration of collagen IV targeted Ac2-26 NPs (in as low as 1 µg peptide per mouse) was shown to significantly block tissue damage in hind-limb ischemia-reperfusion injury by up to 30% in comparison with controls. Together, these findings demonstrate that Ac2-26 NPs are proresolving in vivo and raise the prospect of their use in chronic inflammatory diseases such as atherosclerosis., National Heart, Lung, and Blood Institute (Program of Excellence in Nanotechnology Award Contract HHSN268201000045C), National Institutes of Health (U.S.) (Grant CA151884), Prostate Cancer Foundation (Award in Nanotherapeutics)

Excessive inflammation and failed resolution of the inflammatory response are underlying components of numerous conditions such as arthritis, cardiovascular disease, and cancer. Hence, therapeutics that dampen inflammation and enhance resolution are of considerable interest. In this study, we demonstrate the proresolving activity of sub–100-nm nanoparticles (NPs) containing the anti-inflammatory peptide Ac2-26, an annexin A1/lipocortin 1-mimetic peptide. These NPs were engineered using biodegradable diblock poly(lactic-co-glycolic acid)-b-polyethyleneglycol and poly(lactic-co-glycolic acid)-b-polyethyleneglycol collagen IV–targeted polymers. Using a self-limited zymosan-induced peritonitis model, we show that the Ac2-26 NPs (100 ng per mouse) were significantly more potent than Ac2-26 native peptide at limiting recruitment of polymononuclear neutrophils (56% vs. 30%) and at decreasing the resolution interval up to 4 h. Moreover, systemic administration of collagen IV targeted Ac2-26 NPs (in as low as 1 µg peptide per mouse) was shown to significantly block tissue damage in hind-limb ischemia-reperfusion injury by up to 30% in comparison with controls. Together, these findings demonstrate that Ac2-26 NPs are proresolving in vivo and raise the prospect of their use in chronic inflammatory diseases such as atherosclerosis., National Heart, Lung, and Blood Institute (Program of Excellence in Nanotechnology Award Contract HHSN268201000045C), National Institutes of Health (U.S.) (Grant CA151884), Prostate Cancer Research Foundation (Award in Nanotherapeutics)

Chow Tsun Cheung, Louis., "May 2000.", Thesis (M.D.)--Chinese University of Hong Kong, 2000., Includes bibliographical references., Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web., Mode of access: World Wide Web., s in English and Chinese., http://library.cuhk.edu.hk/record=b6073228, Use of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)